Research
Survodutide — living evidence map
The Atlas page holds the claims; this is how its evidence evolved.
Summary
Survodutide is a dual glucagon and GLP-1 receptor agonist; in a 48-week phase 2 trial in 293 adults with biopsy-confirmed MASH and fibrosis, MASH improved without fibrosis worsening in 43% to 62% on survodutide against 14% on placebo. · pmid:38847460
Identity
PubChem CID 171378821: CID 171378821, C192H289N47O61, 4232 g/mol. · pubchem:171378821
CAS registry number 2805997-46-8. · pubchem:171378821
Where the evidence actually sits
Proportion of the 1 claim about Survodutide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
1 resolved citation, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Survodutide yet.
Dose evidence, rung by rung
No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.
- Approved-label dose · a resolved regulatory document names a labelled dose
nothing resolved on this rung
- Studied human doses · resolved human studies at the established tier
nothing resolved on this rung
- Observational evidence · resolved human data at the emerging tier: thin, or contested
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. · pmid 38847460 · 2024
- Community-reported protocols · protocol propositions from distinct members, counted once per human
nothing resolved on this rung
- Preclinical evidence · resolved animal, cell or mechanistic work
nothing resolved on this rung
1 resolved citation, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.